Position in LQDA
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
4 quarters on record
Common Shares in LQDA Over Time
Shares Held
Position Value (USD)
Derivatives in LQDA
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$3,774,000
PutShares
100,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026ADAR1 Capital Management, LLC holds $31,391,903 across 13 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
1,000,604 | $13,908,395 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
268,391 | $8,083,936 | |
| 3 | BIOA |
BioAge Labs, Inc.
|
135,560 | $2,370,944 | |
| 4 | ALKS |
Alkermes plc.
|
46,400 | $1,640,704 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
|
29,642 | $1,532,194 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
26,913 | $1,295,860 | |
| 7 | BCRX |
Biocryst Pharmaceuticals Inc
|
105,000 | $999,600 | |
| 8 | ELAN |
Elanco Animal Health Inc
|
20,000 | $478,600 |
All Filings in LQDA
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,774,000 | 100,000 | Put | Sole | 2026-05-18 | |
| 2025-12-31 | $845,005 | 24,500 | Put | Sole | 2026-02-18 | |
| 2024-09-30 | $92,850 | 9,285 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $29,500 | 2,000 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||